Caroline Degrugillier-Chopinet

Caroline Degrugillier-Chopinet

Auto-generated profile, based on publicly available information

Caroline Degrugillier-Chopinet

Service de Physiologie & Explorations Fonctionnelles Cardiovasculaires, Centre Hospitalier Universitaire de Lille, Lille, France 4

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GMGabriel Morin
Gabriel Morin
CDCaroline Degrugillier-Chopinet
Caroline Degrugillier-Chopinet
MVMarie Vincent
Marie Vincent
AFAntoine Fraissenon
Antoine Fraissenon
HAHélène Aubert
Hélène Aubert
GCGuillaume Canaud
Guillaume Canaud
PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.